We're Making History
Our corporate journey began in 1992, and since that time Anika has focused tirelessly on leveraging our proprietary HA technology platform to deliver innovative medical solutions for pain management, tissue regeneration and wound healing.
We are proud of our past accomplishments, but we are more excited about our future, including the expansion of our product portfolio and the development of new treatments. Our breakthrough regenerative products are currently distributed worldwide, with expansion opportunities available in the United States, Europe, Asia and the Middle East. Our sights are set on growing our presence in these exciting markets.
Celebrating Over 25 Years of Performance
Explore Anika’s Milestones
Anika celebrates its 25th anniversary.
Anika inaugurates its newly expanded and consolidated state-of-the-art facility to manufacture and package the totality of the company’s diverse portfolio in Bedford, Massachusetts.
Anika completes enrollment in second pivotal Phase III Trial of CINGAL® for the treatment of knee pain associated with osteoarthritis.
Anika wins CE Mark approval for CINGAL®, a formulation of HA plus a steroid for the treatment of osteoarthritis.
Anika receives CE Mark approval for ORTHOVISC®-T, a treatment indicated to relieve pain and restore function in tendons affected by chronic lateral epicondylosis.
Anika receives Health Canada approval for CINGAL®.
Starts trial enrollment for FastTRACK Phase III HYALOFAST® clinical study.
Files investigational device exemption to initiate phase III study to expand the indication of MONOVISC® to treat pain caused by osteoarthritis of the hip.
Anika is ranked #90 on Fortune’s Fastest Growing Companies for 2015.
Anika receives FDA approval to commercialize MONOVISC® in the United States.
Completes trial enrollment for CINGAL®.
Reaches an agreement with Medline Industries, Inc., a world-leading wound care company, for the United States commercialization of HYALOMATRIX®, our leading advanced wound care product.
Anika receives a unique reimbursement code for MONOVISC® effective January 1, 2015 simplifying the reimbursement process and improving patient access.
ORTHOVISC® achieves #1 U.S. market leader position in the multi-injection viscosupplement market.
Anika begins its first full-operation year in a new state-of-the-art pharmaceutical facility in Bedford, MA, USA with expanded capacity and efficiency.
Completes strategic acquisition of Anika Therapeutics S.r.l., a now wholly owned subsidiary by Anika Therapeutics, Inc. based in Abano Terme, Italy.
Anika launches ORTHOVISC® mini, a line extension to treat osteoarthritis symptoms in small joints such as the hands and jaw.
Anika begins commercialization of MONOVISC® in Europe.
Anika receives approval to market ELEVESS®, an aesthetic dermatology product, in the United States, Europe and Canada.
Anika receives approval to market MONOVISC® in Europe. Today, MONOVISC® is available in most countries in Europe through an experienced distributor base.
Anika relocates its corporate facilities and research & development laboratories to expand and enhance the company’s product development and manufacturing capabilities.
Anika receives a unique reimbursement code for ORTHOVISC® effective January 1, 2007 simplifying the reimbursement process and improving patient access.
Anika receives FDA approval and launches ORTHOVISC® in the United States.
Anika establishes a marketing and distribution relationship with Ortho Biotech Products, L.P., a subsidiary of Johnson & Johnson to market ORTHOVISC® in the United States once approved by the FDA.
Anika begins commercialization of its osteoarthritis product, ORTHOVISC®, in Canada.
Anika receives CE Mark approval for ORTHOVISC® for the treatment of the symptoms of osteoarthritis in humans.
The company signs a three-year exclusive distribution agreement with Boehringer Ingelheim Animal Health for its equine osteoarthritis product, HYVISC®.
Anika is incorporated as a spin-off of MedChem Products, Inc.
Anika signs an extension agreement with IOLAB, a Johnson & Johnson subsidiary, to enter into a five-year manufacturing contract for its ophthalmic products, AMVISC® and AMVISC® PLUS. This partnership lasted for 22 years, ending in 2014.